AACR 2022 | Clinical outcomes in women with metastatic HER2-low breast cancer in the real world

Changchuan Jiang, MD, MPH, Roswell Park Comprehensive Cancer Center, Buffalo, NY, explores real-world outcomes in patients with HER2-low breast cancer. In this analysis, it was determined that in the metastatic setting, HER2-low tumors have better survival than HER2-zero tumors, irrespective of hormone receptor status. Specific therapies, such as trastuzumab deruxtecan, have activity in women with HER-low breast cancers and additional therapeutics for HER-2 low should be sought. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.